Latest Capital Structure News

Dotz Nano has secured A$3.3 million through a private placement, backing its next phase of production scale-up and customer engagement under incoming CEO Nati Harpaz.

Vitrafy Life Sciences has launched a non-underwritten Share Purchase Plan to raise approximately A$2 million, offering existing Australian and New Zealand shareholders the chance to buy shares at A$2.60 each, matching the recent institutional placement price.

Strategic Elements Ltd has closed its Share Purchase Plan (SPP) after applications topped $3 million, exceeding the $2.5 million cap. The oversubscription highlights strong shareholder support as the company prepares for a more active phase leveraging the Pooled Development Fund structure.

Beacon Minerals (ASX:BCN) has announced a combined dividend of AUD 0.255 per share for the year ending 30 June 2026, blending a fully franked cash payout with a substantial scrip component tied to Forrestania Resources shares.

Suncorp Group has completed the redemption of all 3.89 million Capital Notes 3, paying holders face value plus a final distribution of A$1.2674 per note on 17 June 2026.

HITIQ Limited secured a Federal Court order extending the quotation period for its HIQOA listed options on the ASX, resolving a regulatory timing issue and validating the delayed admission.

RocketDNA Ltd is acquiring the remaining 40% of its Western Australian subsidiary in a $1 million share-based transaction, simplifying its group structure without operational changes.

Growthpoint Properties Australia sustains strong office leasing momentum in FY26 with 54,721 sqm executed and reaffirmed financial guidance, supported by active capital management and leadership appointments.

Fletcher Building expects FY26 EBIT of $375m-$380m, bolstered by $40m in property sale gains, while executing significant divestments to reduce net debt. The company will withdraw its Moody’s credit rating as it targets a simpler capital structure.

Future Generation Global Limited (ASX:FGG) has updated its special dividend details for the six months ending December 2025, confirming a fully franked 3-cent payout and outlining its dividend reinvestment plan pricing.

ALS Limited has confirmed its ordinary dividend of AUD 0.231 per share for the six months ending March 2026, introducing multi-currency payment options and appointing Macquarie Securities to manage on-market share purchases for its Dividend Reinvestment Plan.

CLINUVEL Pharmaceuticals has lodged its Form 20-F with the U.S. SEC, seeking to elevate its American Depository Receipt program to a Nasdaq-listed American Depository Share, aiming to boost visibility and liquidity without raising capital.